Accessibility Menu
Essex Bio-Technology logo

Essex Bio-Technology(SEHK) 1061

Market CapHK$1.27BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2001)+218%
5 Year-64%
1 Year-56%
1 Month-7%
HK$2.28
+1.79%
+0.04Today
Essex Bio-Technology last closing stock price
MetricPriceDate
Last closeHKD 2.282026-08-31
Essex Bio-Technology stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.88%HKD 2.262026-08-24
1 month-6.56%HKD 2.442026-07-31
3 month-18.86%HKD 2.812026-06-02
Year to date-39.52%HKD 3.772025-12-31
1 year-56.15%HKD 5.202025-08-29
3 year-28.3%HKD 3.182023-08-31
5 year-64.49%HKD 6.422021-09-01
Since inception+218.09%HKD 0.702001-06-27

Essex Bio-Technology Financials at a Glance

Market Cap

HK$1.27BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

HK$3.46B

Net Income (TTM)

HK$578.59M

EPS (TTM)

HK$0.47

P/E Ratio

4.79

Dividend

HK$0.19

Beta (Volatility)

-0.02 (Low)

Price

HK$2.28

Volume

300,000

Open

HK$2.28

Previous Close

HK$2.24

Daily Range

HK$2.28 - HK$2.32

52-Week Range

HK$2.23 - HK$5.63

Estimated Earnings Date

Sep 1, 2026

1061 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Essex Bio-Technology

Essex Bio-Technology Limited is an investment holding company focused on the development, manufacturing, distribution, and sale of biopharmaceutical products. The company operates primarily in the People's Republic of China and has expanded its reach into international markets.

Products and Services
  • Ophthalmic products including Beifushu eye drops and gels
  • Surgical products such as Beifuji sprays and gels for wound care
  • Distribution of third-party ophthalmic and surgical products
Growth Outlook
  • Recent quarterly revenue reached HKD 784.69 million, indicating strong market demand
  • Net income for Q2 2026 was HKD 110.72 million, showcasing profitability
  • Consistent R&D investment supports future product innovation and market expansion
Financial Highlights
  • TTM revenue of HKD 3.24 billion reflects robust sales performance
  • Net profit margin stands at 15.41%, indicating effective cost management
  • Dividend yield of 4.86% offers attractive returns to shareholders
Essex Bio-Technology Limited has established a solid foundation in the biopharmaceutical sector, particularly in ophthalmic and surgical products. The company's commitment to research and development is evident in its diverse product offerings, which cater to both local and international markets. Recent financial performance highlights a strong revenue stream and profitability, making it an intriguing option for potential investors. The company's strategic focus on innovation and market expansion positions it well for future growth in the competitive healthcare landscape.
AI Generated • Aug 11, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1,289

CEO

Hian Leng Ngiam

Website

www.essexbio.com

Headquarters

Zhuhai, GD 519085, CN

1061 Financials

Key Financial Metrics (TTM)

Gross Margin

86.85%

Operating Margin

18.44%

Net Income Margin

15.41%

Return on Equity

10.70%

Return on Capital

13.33%

Return on Assets

7.34%

Earnings Yield

20.88%

Dividend Yield

8.48%

Payout Ratio

29.91%

Stock Overview

Market Cap

HK$1.27BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

566.00M

Volume

300.00K

Avg. Volume

539.73K

Financials (TTM)

Gross Profit

HK$3.05B

Operating Income

HK$664.93M

EBITDA

HK$836.75M

Operating Cash Flow

HK$644.24M

Capital Expenditure

-HK$237.16M

Free Cash Flow

HK$407.09M

Cash & ST Invst.

HK$807.73M

Total Debt

HK$348.99M

Essex Bio-Technology Performance Analysis

Essex Bio-Technology annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31HKD 1,317,710,616-19.5%
20232023-12-31HKD 1,736,972,13431.8%
20242024-12-31HKD 1,669,816,770-3.9%
20252025-12-31HKD 1,813,807,2578.6%
Essex Bio-Technology sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-315.7%
Q22025-06-302.1%
Q42025-12-316.9%
Q22026-06-30-16.3%
Essex Bio-Technology annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31HKD 0.38-34.1%
20232023-12-31HKD 0.4722.5%
20242024-12-31HKD 0.5313.4%
20252025-12-31HKD 0.565.5%
Essex Bio-Technology sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-3.7%
Q22025-06-3011.5%
Q42025-12-31-6.9%
Q22026-06-30-25.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

HK$784.69M

-3.3%

Gross Profit

HK$656.26M

-9.4%

Gross Margin

83.63%

N/A

Market Cap

HK$1.27BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$1.02M

N/A

Employees

1,240

N/A

Net Income

HK$110.72M

-29.7%

EBITDA

HK$168.42M

-15.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

HK$807.73M

+34.5%

Total Debt

HK$348.99M

+6.7%

Accounts Receivable

HK$740.97M

+22.4%

Inventory

HK$87.04M

+20.4%

Long Term Debt

HK$249.00M

+183.5%

Short Term Debt

HK$99.99M

-58.2%

Return on Assets

7.34%

N/A

Return on Invested Capital

11.21%

N/A

Free Cash Flow

HK$73.49M

-39.9%

Operating Cash Flow

HK$101.12M

-23.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About 1061

What is the current price of Essex Bio-Technology?

Essex Bio-Technology is trading at HK$2.28 per share.

What is the 52-week range for Essex Bio-Technology?

Over the past 52 weeks, Essex Bio-Technology has traded between HK$2.23 and HK$5.63.

How much debt does Essex Bio-Technology have?

As of the most recent reporting period, Essex Bio-Technology reported total debt of HK$346.90M.

How much cash does Essex Bio-Technology have on hand?

Essex Bio-Technology reported HK$782.73M in cash and cash equivalents in its most recent financial results.

What is Essex Bio-Technology’s dividend yield?

Essex Bio-Technology currently has a dividend yield of 8.48%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services